Refills
Refills offers GLP-1 care and a broad compounded peptide catalog. Named clinical and pharmacy partners clarify the setup, but its recovery and longevity claims deserve closer scrutiny.
Review by Leah Garner, clinical-evidence editor · Updated October 2026
The short version
Ask the treating clinician to justify the specific preparation and its evidence before considering this service. A pharmacy-quality claim does not establish clinical benefit or blanket permission to compound every item in the catalog.
Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
FDA warning letter on record: Letter 721475 · February 2026
Refills Health LLC operates the platform and collects payments for independent clinical and pharmacy partners. Its live catalog includes weight treatment, sermorelin, NAD, glutathione and numerous experimental peptide protocols. Combination products and broad recovery promises should not be treated as interchangeable medical options.
What Refills prescribes, by goal
Weight
- SemaglutideFDA-approved
- Injection (compounded)Price not published
- TirzepatideFDA-approved
- Injection (compounded)Price not published
The ordinary weight menu separates GLP-1 and dual GIP/GLP-1 injections. The broader peptide guide also names semaglutide and tirzepatide. Obtain the actual medicine and prescription rather than treating a category label as the full formulation.
Sexual health
- PT-141 (bremelanotide)FDA-approved
- Injection (compounded)Price not published
Longevity
- GlutathioneCompounding conditions apply
- Injection (compounded)Price not published
- NAD+Compounding conditions apply
- Injection (compounded)Price not published
Recovery
- SermorelinCompounding conditions apply
- Injection (compounded)Price not published
The catalog markets BPC-157, growth-hormone-related combinations and other research peptides for recovery. A listed prescription pathway does not establish proven benefit or an eligible compounded preparation under every circumstance.
Sleep
- SermorelinCompounding conditions apply
- Injection (compounded)Price not published
Who prescribes
A licensed clinician
The terms identify a clinical network including Wasef Health professional corporation, with Beluga Health and other partners also named publicly. PerfectRx and Hallandale appear on the pharmacy page; the terms list additional fulfillment partners. Ask which clinician and pharmacy will actually handle the prescription. General partner lists do not establish an individual assignment.
A health assessment precedes clinician review and a possible prescription. The program describes online follow-up and adjustment when treatment is ineffective. A guaranteed video schedule is not established for every protocol. Ask who handles adverse effects and how reassessment works before accepting several medicines together.
Are labs required?
Patient testing and charges require confirmation
The intake description permits a clinician to order tests when needed. The product-purity and sterility claims refer to medication testing, not an included patient laboratory panel. A universal patient-testing schedule or charge was not established.
Ready to start with Refills?
Prices and plans are set on the seller's own site.
What it claims, and what it cites
FDA warned Refills Health in February 2026 after a December 2025 website review. It objected to pictured labels implying that Refills compounded semaglutide and claims implying FDA evaluation or approval. No closeout was confirmed. The current catalog makes broad repair, cognitive and hormonal claims. Its regulatory explanation should not replace preparation-specific advice: compounded drugs lack FDA approval, and prescribing and pharmacy conditions still apply. Ask about meaningful human outcomes, adverse effects and alternatives rather than relying on a certificate of analysis alone.
Other products and treatment claims
- AOD-9604
- On no FDA compounding list. AOD-9604 appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).
- BPC-157
- On no 503A list (removed from Category 2 in April 2026, never in Category 1). The FDA's compounding advisory committee voted 8–6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
- CJC-1295
- On no FDA compounding list. The name does not appear in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025), so neither a 503A pharmacy nor a 503B outsourcing facility has a listed route to it.
- Ipamorelin
- "Ipamorelin Acetate" is in 503B Category 2, bulk drug substances that raise significant safety risks (list updated March 21, 2025). It is named on no 503A list, so neither an outsourcing facility nor a 503A pharmacy has a listed route to it.
- DSIP
- On no FDA compounding list. The name does not appear in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025).
- Epitalon
- On no FDA compounding list. Neither "Epitalon" nor "Epithalon" appears in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025).
- Kisspeptin
- Kisspeptin-10 is in 503A Category 2 (bulk drug substances that raise significant safety risks), placed there September 29, 2023 and still listed in the May 14, 2026 update. FDA cites a possible risk of immunogenicity and peptide-related impurities, and says it has no, or only limited, safety information for the proposed routes.
- LL-37
- On no FDA compounding list. Neither LL-37 nor cathelicidin, the family it belongs to, appears in the 503A bulk drug substances categories (updated May 14, 2026) or the 503B categories (updated March 21, 2025).
- MOTS-c
- On no 503A list (not in Categories 1–3 of the May 14, 2026 update). The FDA's compounding advisory committee voted 7–5 (two abstentions) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
- Semax
- On no FDA compounding list. Semax appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).
- Tesamorelin
- Approved only as Egrifta, for excess abdominal fat in adults with HIV-associated lipodystrophy. Its label says it is not indicated for weight loss. Egrifta became a biologic (BLA) on March 23, 2020, and FDA says compounded versions of these products do not qualify for the 503A or 503B compounding exemptions.
- Selank
- On no FDA compounding list. Selank appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).
- TB-500
- On no FDA compounding list: absent from the 503A categories (updated May 14, 2026) and the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
- GHK-Cu
- "GHK-Cu (except for injectable routes of administration)" is in 503A Category 1 (list updated May 14, 2026). The injectable route is on no list.
- Thymosin alpha-1
- "Thymosin alpha-1" is in 503B Category 3, bulk drug substances nominated without adequate support (list updated March 21, 2025). It is named on no 503A list, so no listed compounding route exists for it.
How it bills
The homepage advertises treatment from $5 per day, without establishing a complete flexible monthly charge for each prescription. Terms describe a combined subscription payment covering pharmacy, professional and platform portions. Ask for the actual amount and included services. Subscriptions must be stopped at least seventy-two hours before the monthly processing date. The return page also refers to acting before the order reaches the pharmacy. Its general statement about shipping no refrigerated products needs prescription-specific clarification alongside injectable offerings.
For and against
- For: Clinical and pharmacy partners identified
- For: Consultation precedes a prescription
- For: Cancellation processing deadline stated
- Against: Many treatment claims need stronger scrutiny
- Against: Complete monthly prices unresolved
- Against: Storage and order-stage details require clarification
The evidence behind what it sells
- Semaglutide Side Effects: What the Wegovy Trials and Label Recorded
- Bremelanotide Side Effects: Nausea, Blood Pressure and Skin Darkening
- Glutathione Side Effects: What Injection, IV and Oral Studies Reported
- Sermorelin Side Effects: What the Trials and FDA Record Report
- Tirzepatide Side Effects: What the Zepbound Label and Trials Recorded
- Bremelanotide (PT-141): The FDA Approval and What the Trials Showed
Right for
Someone willing to obtain a preparation-specific clinical explanation and written pharmacy assignment before considering a broader peptide protocol.
Look elsewhere if
Someone treating the large catalog or pharmacy testing claims as proof that every protocol is effective and appropriate.
Other sellers for weight
Dr. Gillis’ Wellness Center
Also prescribes Semaglutide, Tirzepatide.
Vita Bella
Also prescribes Semaglutide, Tirzepatide.
Rylo Health
Also prescribes Semaglutide, Tirzepatide.
Refills
Frequently asked questions
- Does Refills itself prescribe or compound?
- Its terms describe a separate technology and payment role. Independent professional practices prescribe, and pharmacy partners fulfill the order.
- Does every product have a monthly quote?
- No. The daily headline does not establish the complete medication-specific monthly payment.
- Was the FDA letter closed?
- A closeout was not confirmed. The letter concerns the named company’s historical semaglutide marketing and pictured labels.
Sources
- Current treatment and dose-price claims
- Live compounded peptide catalog and preparations
- Clinical roles, billing and cancellation deadline
- Prescription returns and delivery remedies
- Named pharmacy partners
- Sermorelin administration
- NAD injection disclosures
- FDA warning letter721475
See what Refills prescribes today
Refills sets its own prices, plans and the states it serves. Check them before you start.